Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,922 recruiting studies in this area right now.
By phase
- Not applicable2,026
- Phase 21,073
- Phase 1790
- Phase 1/Phase 2479
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California395
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,922 total
- NCT07249073RecruitingEarly Phase 1
Dual-target CAR-T for relapsed/refractory myeloma
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07240974RecruitingEarly Phase 1
Study of ZZSW-01 for B-cell blood cancers that returned or didn't respond
This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.
WuhanAges 18 years+ - NCT07244367Recruiting
Venetoclax maintenance for AML fit patients
This trial tests whether taking venetoclax can help keep your leukemia from coming back after you reach complete remission. It is for patients who are not able to get a bone marrow transplant right away.
SohagAges 18–60 - NCT07246213Recruiting
Childhood cancer survivor research study
This study looks back at the medical records of children and young adults diagnosed with cancer in the last 15 years. It helps researchers understand more about cancer in young people.
YerevanAges birth–21 years - NCT07246265Recruiting
Morphine clearance study for sickle cell crisis in ICU
This study looks at how the body clears morphine in adults with sickle cell disease who are in the intensive care unit (ICU) for a pain crisis or acute chest syndrome and are receiving morphine through a patient-controlled analgesia (PCA) pump. The goal is to understand how kidney function affects morphine breakdown.
Tours, FranceAges 18 years+ - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80 - NCT07243483Recruiting
Studying venetoclax in untreated acute myeloid leukemia
This study looks at how the body processes venetoclax when it's given with azacitidine as a first treatment for acute myeloid leukemia (AML). It aims to understand how well the drug works and how the body handles it.
Bourgoin, FranceAges 18 years+ - NCT06082947Recruiting
Stem cell transplant with special cell depletion for children and young adults
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
Columbus, OhioAges Up to 30 years - NCT06735625Recruiting
AHSP as a biomarker for sickle cell disease
This study looks at a substance in the blood called AHSP to see if it can help track sickle cell disease. It compares people with sickle cell disease (SS or Sβ0 type) to people without it, to better understand the condition.
Saint-DenisAges 3 years+ - NCT06484829RecruitingPhase 1/Phase 2
New drug combo for relapsed or refractory multiple myeloma
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Chengdu, SichuanAges 18–75 - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06897605RecruitingPhase 2
Dapagliflozin for anemia in kidney disease
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
Al MansurahAges 18 years+ - NCT06896344Recruiting
How cell particles affect blood stem cells in myelofibrosis
This trial is looking at whether tiny particles released by certain cells from people with myelofibrosis can affect their blood-forming stem cells. The goal is to understand the disease better and find new treatments.
Pavia, PaviaAges 18 years+ - NCT05530096Recruiting
Genetic test to find minimal residual myeloma in remission
This study tests a genetic technology (ClonoSeq-based) to detect very small amounts of multiple myeloma that may remain after treatment. It may help doctors better track how well treatment is working and predict how the disease responds over time.
Montreal, QuebecAges 18 years+ - NCT05567289Recruiting
Precision medicine after stem cell transplant
This study looks at a personalized (“precision”) approach for people who have received a stem cell transplant from a donor. It may help doctors better tailor care after transplant, especially for children.
ManchesterAges Any age - NCT06629311Recruiting
Blood recycling device study in heart surgery
This trial looks at how a device that collects and reuses your own blood during heart surgery works. It may help reduce the need for donated blood.
Strasbourg, Bas-RhinAges 18 years+ - NCT07233720Recruiting
Zanubrutinib plus rituximab for first-line marginal zone lymphoma
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
Zhengzhou, HenanAges Any age - NCT07233863Recruiting
Lymphovenous bypass for preventing lymphedema in breast cancer
This trial tests a surgery (lymphovenous bypass) to prevent or slow down lymphedema (arm swelling) in breast cancer patients who have already had lymph nodes removed. It may help those with early-stage lymphedema who haven't tried physical therapy yet.
Jakarta, Jakarta Special Capital RegionAges 18 years+ - NCT07234825Recruiting
Trial of dairy-free diet with liquid nutrition for eosinophilic esophagitis
This study tests whether a dairy-free diet combined with a special liquid nutrition drink (called Kate Farms) can help children and young adults with eosinophilic esophagitis (a condition where certain white blood cells build up in the esophagus and cause trouble swallowing, pain, or vomiting). The goal is to see if this combination can reduce symptoms and improve quality of life.
Seattle, WashingtonAges 1–21 - NCT07233213RecruitingPhase 3
IVIG for chronic low platelet condition
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Ankara, AltındağAges 18–65 - NCT07234162RecruitingPhase 3
Study comparing golidocitinib to standard therapy for relapsed T-cell lymphoma
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hefei, AnhuiAges 18 years+ - NCT07239323RecruitingPhase 1
CAR-T therapy for blood cancers that have returned or not responded
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Kunming, YunnanAges 18 years+ - NCT07232290RecruitingPhase 2
Flonoltinib for people with polycythemia vera
This study tests a new pill, flonoltinib, for people with polycythemia vera whose blood counts are hard to control and who have not responded well to or couldn't tolerate current treatments. The goal is to see if the pill can lower the number of red blood cells and reduce symptoms, potentially reducing the need for frequent blood removal procedures.
TianjinAges 18 years+ - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,922 recruiting hematology studies from the U.S. registry right now, out of 7,323 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.